[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"post-acute-sequelae-of-covid-19\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:post-acute-sequelae-of-covid-19":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,47,74,105,128,151],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100586841","phase-1-pet-imaging-of-cyclooxygenase-1-in-participants-with-neurological-manifestations-of-post-acute-sequelae-of-sars-cov-2-infection-pasc-100586841",false,"NCT06920628","PET Imaging of Cyclooxygenase-1 in Participants With Neurological Manifestations of Post-Acute Sequelae of SARS-CoV-2 Infection (PASC)","* INCLUSION CRITERIA:\n\nPatients: To be eligible for this study, Neuro-PASC participants must meet all of the following criteria:\n\n* Aged 18 to 70 years of age.\n* Participants must be in good general health as evidenced by medical history and physical examination.\n* Each participant must have a level of understanding sufficient to agree to all required tests and examinations and sign an informed consent document.\n* Participants must have undergone a screening assessment under protocol #000089, Natural History of Post-Coronavirus Disease 19 Convalescence at the National Institutes of Health or #000711 Immunotherapy for Neurological Post-Acute Sequelae of SARSCoV-2 (INPASC) and determined to have neuro-PASC.\n* Participants must have had their radial artery pulse checked for the presence of adequate ulnar collateral flow and the absence of any metal or foreign objects in both wrists.\n* Participants must agree to adhere to the lifestyle considerations.\n\nHealthy Volunteers: To be eligible to participate in this study, healthy volunteers must meet all of the following criteria:\n\n* Aged 18 to 70 years of age.\n* Able to provide informed consent.\n* Be in good general health, as evidenced by medical history and physical examination, and have no cognitive impairment.\n* Does not have an active SARS-CoV-2 infection. The protocol will conform with NIH CC standards for documenting a participant does not have active SARS-CoV-2 infection. This may include screening interviews and\u002For testing.\n* Participants must be at least six weeks out since the onset of SARS-CoV-2 symptoms with no fever for at least one week.\n* Participants must report having at least one prior SARS-CoV-2 infection.\n* Be enrolled in 01M0254, The Evaluation of Participants with Mood and Anxiety Disorders and Healthy Volunteers or 17M0181, Recruitment and Characterization of Healthy Research Volunteers for NIMH Intramural Studies .\n* Have had their radial artery pulse checked for the presence of adequate ulnar collateral flow and the absence of any metal or foreign objects in both wrists.\n* Agree to adhere to the lifestyle considerations.\n\nEXCLUSION CRITERIA:\n\nParticipants with Neuro-PASC who meet any of the following criteria will be excluded from participation in this study:\n\n* Clinically significant abnormalities on EKG or laboratory testing based on individual clinical judgement. This includes CBC and acute care panel (Na, K, Cl, CO2, creatinine, glucose, urea nitrogen). Any lab value that is two times the upper limit or lower values, as per the investigator s judgment. Creatinine level \\>1.3 mg\u002FdL.\n* Participants should not have taken Non-Steroidal Anti-Inflammatory Drug (NSAID)s for two weeks prior to each PET scan. Corticosteroids (with the exception of topical steroids), or immunosuppressants (e.g. methotrexate) must not have been taken within one month prior to each PET scan.\n* Participants must not have substance use disorder or alcohol use disorder. However, alcohol or cannabis use by themselves are not exclusion criteria, unless that use impairs daily life functions.\n* Participants who have an unstable medical condition that, in the opinion of the investigators, makes participation unsafe (e.g., an active infection or untreated malignancy).\n* Are unable to travel to the NIH.\n* Have recent exposure to radiation related to research (e.g., PET from other research) that, when combined with this study, would be above the allowable limits as determined by the study team.\n* Have an inability to lie flat and\u002For lie still on the camera bed for at least two hours,including claustrophobia, overweight greater than the maximum for the scanner, and uncontrollable behavioral symptoms, which will be screened by an interview with the participant during the screening visit.\n* Are unable to have an MRI scan (e.g., because of pacemakers or other implanted electrical devices, brain stimulators, dental implants, aneurysm clips (metal clips on the wall of a large artery), metallic prostheses (including metal pins and rods, heart valves, and cochlear implants), permanent eyeliner, implanted delivery pumps, shrapnel fragments, or metal fragments in the eye.\n* Pregnancy or Breastfeeding Women.\n* HIV Infection.\n\nHealthy volunteers who meet any of the following criteria will be excluded from participation in this study:\n\n* Clinically significant abnormalities on EKG or laboratory testing. This includes CBC and acute care panel (Na, K, Cl, CO2, creatinine, glucose, urea nitrogen).\n* Participants should not have taken Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) for two weeks prior to the PET scan. Corticosteroids (with the exception of topical steroids), or immunosuppressants (e.g., methotrexate) must not have been taken within one month prior to the PET scan.\n* Participants with an active SARS-CoV-2 infection.\n* Participants must not have substance use disorder or alcohol use disorder. However, alcohol or cannabis use by themselves are not exclusion criteria, unless that use impairs daily life functions.\n* Are unable to travel to the NIH.\n* Have recent exposure to radiation related to research (e.g., PET from other research) that, when combined with this study, would be above the allowable limits.\n* Have an inability to lie flat and\u002For lie still on the camera bed for at least two hours, including claustrophobia, overweight greater than the maximum for the scanner, and uncontrollable behavioral symptoms, which will be screened by an interview with the participant during the screening visit.\n* Are unable to have an MRI scan (e.g., because of pacemakers or other implanted electrical devices, brain stimulators, dental implants, aneurysm clips (metal clips on the wall of a large artery), metallic prostheses (including metal pins and rods, heart valves, and cochlear implants), permanent eyeliner, implanted delivery pumps, shrapnel fragments, or metal fragments in the eye.\n* Pregnancy or Breastfeeding Women.\n* HIV Infection.",true,"ALL","18 Years","70 Years",{"count":20,"type":21},60,"ESTIMATED","INTERVENTIONAL",[24],"PHASE1","Background:\n\nSARS-CoV-2 is the virus that causes COVID-19. Some people who recover from COVID-19 have long-term symptoms that affect the brain. These include headaches; loss of taste and smell; sleep problems; thinking problems; depression; and anxiety. Researchers want to know if a tracer (a substance that is injected into a person s body before an imaging scan) can help identify inflammation in people with these brain disorders.\n\nObjective:\n\nTo see if a radioactive tracer (\\[11C\\]PS13) can highlight brain inflammation in those who had COVID-19 but still have symptoms that affect the brain.\n\nEligibility:\n\nAdults aged 18 to 70 years with post COVID-19 brain disorders who are enrolled in protocol 000089 or 000711. Healthy volunteers are also needed.\n\nDesign:\n\nParticipants will have up to 5 clinic visits.\n\nParticipants will be screened. They will have blood tests and a test of their heart function.\n\nThey will have imaging scans:\n\nMagnetic resonance imaging (MRI): They will lie on a table that slides into a metal tube. Pictures will be taken of the brain.\n\nPositron emission tomography (PET): A needle attached to a thin tube will be inserted into a vein in the arm. The tracer will be injected through the tube. Another needle attached to a thin tube will be inserted into the wrist or inside of the elbow of the other arm to draw blood. They will lie still on a bed while a machine captures images of their brain. The scan will last about 2 hours.\n\nStudy involvement is 11 to 14 weeks....",[27,28],"Long COVID","Post Acute Sequelae of COVID-19",[30,31,32,33],"Inflammation","COVID","SARS","Neuro-PASC","RECRUITING","2026-06-16",{"date":37,"type":38},"2026-06-17","ACTUAL",{"date":40,"type":38},"2025-06-18",{"date":42,"type":21},"2029-02-22",{"name":44,"class":45},"National Institute of Mental Health (NIMH)","NIH",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":55,"enrollmentInfo":56,"targetDuration":4,"studyType":22,"phases":58,"briefSummary":60,"conditions":61,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":46},"100637180","phase-2-sars-cov-2-and-herpesvirus-inhibition-for-ending-long-covid-dysfunction-100637180","NCT07597902","SARS-CoV-2 and Herpesvirus Inhibition for Ending Long COVID Dysfunction","SARS-CoV-2 and Herpesvirus Inhibition for Ending Long COVID Dysfunction (SHIELD)","SHIELD","Inclusion Criteria:\n\n* 18-65 years of age at the time of study entry\n* Diagnosed with Long COVID\n* Individuals of child-bearing potential must have a negative serum pregnancy test at screening and agree to on-site urine pregnancy testing at all subsequent study visits\n* A urine drug screen performed at the Screening Visit must be negative for drugs of abuse such as methamphetamine, cocaine, phencyclidine (PCP), and non-disclosed amphetamines and opioids\u002Fopiates.\n* Those with mild to moderate depression should be clinically stable for three months, without risk of suicidal ideation or behavior.\n\nExclusion Criteria:\n\n* Breastfeeding, pregnant, or planning to become pregnant during the next six months.\n* In the opinion of the Investigator, any clinically significant, uncontrolled, or unstable medical or surgical condition that could affect the individual's ability to participate in the study or potentially compromise their well-being while enrolled in the study.\n* In the opinion of the Investigator or based on results of the HADS, evidence of a clinically significant psychiatric disorder, e.g., severe, unstable or poorly controlled depression, anxiety or obsessive-compulsive disorder; moderate or severe alcohol use disorder; substance use disorder other than mild cannabis use disorder; or any history of bipolar disorder, schizophrenia, schizoaffective disorder or other psychotic disorder.\n* Currently meeting criteria for ME\u002FCFS at the pre-screening or screening visit, or a prior confirmed diagnosis of ME\u002FCFS within the last 5 years. This may be determined as part of the initial screening call or visit.\n* Any anticipated need for surgery that in the opinion of the Principal Investigator or Sub-I might confound results or interfere with the participant's ability to comply with the protocol.\n* Symptomatic and\u002For otherwise clinically significant cardiac disease\n* Acute non-COVID systemic infection (e.g., HIV, hepatitis) or other active viral or bacterial infection during the screening\u002Fwashout period or at the Baseline visit.\n* Currently receiving chronic systemic corticosteroids (\\>5 mg prednisone daily, or equivalent)\n* Routine treatment with warfarin, heparin, lithium, digoxin, amiodarone, isoniazid, phenytoin, fluconazole, methotrexate, probenecid, or raloxifene. Participants on these medications should not be screened.\n* Uncontrolled sleep apnea.\n* Use of chronic nucleoside analog antiviral suppression therapy within one month of the Screening Visit or requiring on average more than one acute treatment course every two months.\n* Current use of celecoxib either alone or in combination with valacyclovir or famciclovir\n* In the opinion of the Investigator, evidence of current drug or alcohol abuse or dependency, or history of abuse or dependence during the preceding 12 months.\n* The participant has undergone a malabsorptive weight loss procedure (e.g., Roux-en-Y or other bypass procedure).\n* Severe IBS-C or colonic inertia as evidenced by seven or more days between bowel movements.","65 Years",{"count":57,"type":21},150,[59],"PHASE2","The purpose of this research study is to test if the combination of three drugs, valacyclovir, celecoxib, and Paxlovid will decrease the symptoms of Long COVID in adults compared to a placebo (this does not contain the medications).",[62,27],"Post-acute Sequelae of COVID-19","NOT_YET_RECRUITING","2026-05-14",{"date":66,"type":38},"2026-05-19",{"date":68,"type":21},"2026-06-01",{"date":70,"type":21},"2028-06-30",{"name":72,"class":73},"Icahn School of Medicine at Mount Sinai","OTHER",{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":80,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":82,"enrollmentInfo":83,"targetDuration":4,"studyType":22,"phases":85,"briefSummary":87,"conditions":88,"keywords":93,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":46},"100443689","autoimmune-intervention-mastery-course-study-100443689","NCT05057676","Autoimmune Intervention Mastery Course Study","Evaluation of an Online Course Designed to Support the Adoption of Healthier Diet and Self-Care Routines in Multiple Sclerosis Patients","AIM","Inclusion Criteria:\n\n* self-reported multiple sclerosis\n* self-reported clinically isolated syndrome\n\nOR self-reported post-acute sequelae of COVID (PASC), also known as long COVID, with a confirmed laboratory test of COVID-19 infection, persisting fatigue and neuropsychiatric symptoms for longer than 6 months after confirmation of COVID diagnosis,\n\nOR self-reported diagnosis of fibromyalgia as documented by their treating specialist or primary care provider,\n\nExclusion Criteria:\n\n\\-","100 Years",{"count":84,"type":21},400,[86],"NA","The goal of this project is to critically evaluate the effectiveness of using an online program to improve diet and self-care in patients with multiple sclerosis (MS), clinically isolated syndrome (CIS), fibromyalgia, post acute sequela of covid, and cancer in remission with persisting fatigue.",[89,90,91,28,92],"Multiple Sclerosis","Clinically Isolated Syndrome","Fibromyalgia","Cancer in Remission With Persisting Fatigue",[94,95],"diet","self care","2026-03-09",{"date":98,"type":38},"2026-03-11",{"date":100,"type":38},"2021-12-01",{"date":102,"type":21},"2027-12-01",{"name":104,"class":73},"Terry L. Wahls",{"id":106,"slug":107,"hasResults":11,"nctId":108,"briefTitle":109,"officialTitle":110,"acronym":111,"eligibilityCriteria":112,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":113,"targetDuration":4,"studyType":22,"phases":115,"briefSummary":116,"conditions":117,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":120,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":126,"locationsCount":46},"100550824","recovering-from-covid-19-lingering-symptoms-adaptive-integrative-medicine-trial---effect-of-hyperbaric-oxygen-therapy-for-the-treatment-of-post-covid-condition-100550824","NCT06452095","Recovering From COVID-19 Lingering Symptoms Adaptive Integrative Medicine Trial - Effect of Hyperbaric Oxygen Therapy for the Treatment of Post COVID Condition","RECLAIM: Recovering From COVID-19 Lingering Symptoms Adaptive Integrative Medicine Trial - Effect of Hyperbaric Oxygen Therapy for the Treatment of Post COVID Condition (RECLAIM-HBOT)","RECLAIM-HBOT","Inclusion Criteria:\n\n1. Age ≥18 years;\n2. Positive COVID-19 test by nasopharyngeal swab RT-PCR (reverse transcription polymerase chain reaction) test, antibody or antigen tests at least 3 months prior to randomization; OR Presumed COVID-19 assessed by the site investigator (no positive COVID-19 test) with acute illness after October 15, 2019.\n3. Patients should be treated with standard of care therapies (as discussed in the study manual) for at least 4 weeks prior to entry into trial.\n4. Lingering COVID-19 symptoms beyond 3 months from onset of acute COVID and symptoms have lasted at least 2 months. The onset of COVID is considered the earliest of two dates: the date of positive test or the date of first symptoms;\n5. Lingering symptoms from COVID-19 present at the time of randomization. \"Lingering symptoms of Long COVID\" must include self-reported cognitive dysfunction symptoms.\n6. Female patients of childbearing potential (as assessed by the overseeing Investigator) who are sexually active must agree to practice true abstinence or use effective methods of contraception while on study treatment. Effective methods of contraception must be discussed and approved by the overseeing Investigator.\n7. Must be able to provide informed consent and both willing and able to comply with study requirements.\n8. A confirmed ability to travel to one of the three sites where HBOT or sham can be administered.\n\nExclusion Criteria:\n\n1. Patients who had mechanical ventilation or extracorporeal membrane oxygen (ECMO) for COVID-19;\n2. Current end-organ failure, organ transplantation, or current hospitalization in acute care hospital;\n3. Contraindications to all of the study interventions;\n4. Co-enrolment in another interventional trial (co-enrolment in an observational study is permitted);\n5. Currently pregnant or breastfeeding.\n6. Pneumothorax\n7. Poorly controlled seizure disorder\n8. Chronic sinusitis\n9. Chronic or acute otitis media\n10. Major ear drum trauma.",{"count":114,"type":21},120,[86],"The RECLAIM study platform will be used to explore whether the use of Hyperbaric Oxygen therapy (HBOT) improves the symptoms of post covid cognitive dysfunction.\n\nHyperbaric oxygen therapy is a well-established medical treatment. HBOT promotes healing by delivering a high concentration of oxygen into the body. This high level of oxygen has a number of known benefits, such as growth of new blood vessels, as well as regulating immune and inflammation responses. It helps protect the brain and other nervous tissue from inflammation. HBOT may also have antiviral effects.\n\nCollectively, it has the potential to target the underlying mechanisms believed to play a critical role in the development of Long COVID.\n\nMany individuals with Long COVID complain of fatigue, brain fog, muscle aches and other symptoms. There is evidence to suggest that these symptoms may be a problem with the blood vessels, resulting in abnormal delivery of oxygen to tissues. Thus, our group is investigating whether HBOT improves post-COVID cognitive dysfunction.",[27,28,118],"Post-COVID-19 Condition","2026-02-19",{"date":121,"type":38},"2026-02-23",{"date":123,"type":38},"2026-01-01",{"date":125,"type":21},"2029-12-31",{"name":127,"class":73},"University Health Network, Toronto",{"id":129,"slug":130,"hasResults":11,"nctId":131,"briefTitle":132,"officialTitle":133,"acronym":4,"eligibilityCriteria":134,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":55,"enrollmentInfo":135,"targetDuration":4,"studyType":22,"phases":137,"briefSummary":138,"conditions":139,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":142,"lastUpdatePostDateStruct":143,"startDateStruct":145,"completionDateStruct":147,"leadSponsor":149,"locationsCount":46},"100519575","mind-body-intervention-for-long-covid-19-100519575","NCT06045338","Mind Body Intervention for Long COVID-19","Mind Body Intervention for Long COVID","Inclusion Criteria:\n\n1. Adult (≥ 18 years of age)\n2. Infection with Sars-COV2 (i. e., positive antibody, antigen, or PCR testing)\n3. Symptoms attributed only to COVID-19 and not to known comorbid disease (e.g., other infections, cancer, etc)\n4. A somatic symptom score ≥ 10 on the SSS-8 questionnaire with involvement of at least 3 domains\n5. Symptoms present at least 3 day a week for a minimum of 3 months\n6. Willingness to engage in a Mind-Body intervention\n\nExclusion Criteria:\n\n1. Clear diagnosis of physical disease (e.g. lung fibrosis, myocarditis) not inclusive of non-specific findings such as mild arthritis\n2. Hospitalization in an intensive care unit for acute COVID-19 infections\n3. Age greater than 65 years\n4. Diagnosis of dementia or similar cognitive impairment\n5. Active addiction disorder (e.g. cocaine) that would interfere with study participation\n6. Major psychiatric comorbidity (e.g., schizophrenia). Mild to moderate anxiety and depression are not considered in this category",{"count":136,"type":21},180,[86],"The goal of this study is to determine if a mind-body intervention can help people suffering from symptoms associated with Long COVID. The study is a randomized trial examining the effectiveness of a mind body intervention in reducing somatic symptoms from Long COVID in participants as compared to usual care and an active control (second mind body intervention). The investigators will secondarily investigate whether the intervention alleviates individual somatic complaints and improves daily functioning, relative to usual care and the active control",[27,140,141],"Post-Acute Sequelae of COVID-19","COVID Long-Haul","2026-02-16",{"date":144,"type":38},"2026-02-18",{"date":146,"type":38},"2023-11-09",{"date":148,"type":21},"2026-12",{"name":150,"class":73},"Beth Israel Deaconess Medical Center",{"id":152,"slug":153,"hasResults":11,"nctId":154,"briefTitle":155,"officialTitle":156,"acronym":157,"eligibilityCriteria":158,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":159,"targetDuration":4,"studyType":22,"phases":160,"briefSummary":161,"conditions":162,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":164,"lastUpdatePostDateStruct":165,"startDateStruct":167,"completionDateStruct":169,"leadSponsor":171,"locationsCount":172},"100587447","effect-of-hi-oxsr-for-the-treatment-of-post-covid-condition-100587447","NCT06928506","Effect of Hi-OxSR for the Treatment of Post COVID Condition","RECLAIM: Recovering From COVID-19 Lingering Symptoms Adaptive Integrative Medicine Trial - Effect of Hi-OxSR for the Treatment of Post COVID Condition (RECLAIM-HiOxSR)","RECLAIM-HiOxSR","Inclusion Criteria:\n\n1. Age ≥18 years;\n2. Positive COVID-19 test by nasopharyngeal swab RT-PCR (reverse transcription polymerase chain reaction) test, antibody or antigen tests at least 3 months prior to randomization; OR Presumed COVID-19 assessed by the site investigator (no positive COVID-19 test) with acute illness after October 15, 2019.\n3. Patients should be treated with standard of care therapies (as discussed in the study manual) for at least 4 weeks prior to entry into trial.\n4. Lingering COVID-19 symptoms beyond 3 months from onset of acute COVID and symptoms have lasted at least 2 months. The onset of COVID is considered the earliest of two dates: the date of positive test or the date of first symptoms;\n5. Lingering symptoms from COVID-19 present at the time of randomization. \"Lingering symptoms of Long COVID\" must include self-reported cognitive dysfunction symptoms.\n6. Female patients of childbearing potential (as assessed by the overseeing Investigator) who are sexually active must agree to practice true abstinence or use effective methods of contraception while on study treatment. Effective methods of contraception must be discussed and approved by the overseeing Investigator.\n7. Must be able to provide informed consent and both willing and able to comply with study requirements.\n8. Oxygen saturation on room air ≥92% at screening measured by pulse oximeter.\n\nExclusion Criteria:\n\n1. Patients who had mechanical ventilation or extracorporeal membrane oxygen (ECMO) for COVID-19;\n2. Current end-organ failure, organ transplantation, or current hospitalization in acute care hospital;\n3. Contraindications to all of the study interventions;\n4. Co-enrolment in another interventional trial (co-enrolment in an observational study is permitted);\n5. Currently pregnant or breastfeeding.\n6. Known physician diagnosis of cognitive dysfunction prior to COVID infection\n7. Use of an investigational drug\u002Fdevice or other interventions within 30 days of screening\n8. Use of home oxygen (O2) at baseline\n9. History of pulmonary hypertension\n10. Interstitial pulmonary fibrosis\n11. Moderate to severe chronic obstructive pulmonary disease (COPD)\n12. History of narcolepsy\n13. Presence of a condition or abnormality that in the opinion of the investigator would compromise the safety of the participant or the quality of the data.",{"count":114,"type":21},[86],"The RECLAIM study platform will be used to explore whether the use of the Hi-OxSR device improves the symptoms of post covid cognitive dysfunction. Carbon dioxide (CO2) has been proposed as a potential treatment for persistent immune activation as there is evidence that CO2 has antioxidant, anti-inflammatory, and anti-cytokine effects. We conducted a pilot study assessing the open label use of re-breathing CO2 (using Hi-OxSR) twice a day for 14 days, for the treatment of post-COVID cognitive dysfunction. Significant improvements were found in multiple cognitive assessments using TestMyBrain cognitive tests and brain fog (MSNQ) and fatigue scores. This phase 2 clinical trial seeks to build on current findings to determine the optimal effective dose of treatment (i.e. length of use, oxygen concentration, without or without CO2 rebreathing) and the safety of using Hi-OxSR in this patient population.",[27,163,28],"Post COVID-19 Condition","2025-09-11",{"date":166,"type":38},"2025-09-15",{"date":168,"type":38},"2025-08-01",{"date":170,"type":21},"2028-12",{"name":127,"class":73},3]